Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Neurol Sci. 2014 Jan 15;336(1-2):127-31. doi: 10.1016/j.jns.2013.10.022. Epub 2013 Oct 22.

β-Blockers associated with no class-specific survival benefit in acute intracerebral hemorrhage.

Author information

  • 1The University of Connecticut School of Medicine, United States. Electronic address: JShoup@student.uchc.edu.
  • 2The University of Connecticut School of Medicine, United States. Electronic address: JWinkler@student.uchc.edu.
  • 3The University of Connecticut School of Medicine, United States. Electronic address: ACzap@student.uchc.edu.
  • 4Hartford Hospital Research Department, United States. Electronic address: IStaff@harthosp.org.
  • 5Hartford Hospital Research Department, United States. Electronic address: GFortun@harthosp.org.
  • 6The University of Connecticut Health Center, Departments of Neurology and Neuroscience, United States; The Stroke Center at Hartford Hospital, United States. Electronic address: LMcCullough@uchc.edu.
  • 7The Stroke Center at Hartford Hospital, United States. Electronic address: Sansing@uchc.edu.

Abstract

OBJECTIVES:

Despite the high mortality, there is currently no specific treatment for intracerebral hemorrhage (ICH). Research investigating optimum degree of blood pressure control in patients presenting with ICH and hypertension is ongoing. However, there is limited understanding of the potential benefits of specific classes of antihypertensive therapy. β-Adrenergic antagonists may provide neuroprotection from inflammation-induced injury by inhibiting sympathetic nervous system mediated immune activation. We examined mortality in ICH patients receiving β-adrenergic antagonists to determine whether this class of antihypertensive therapy was associated with improved survival.

METHODS:

A retrospective analysis of a large, prospectively collected database of patients presenting with acute ICH was performed. Patients were grouped by inpatient β-blocker treatment to determine an effect on mortality during the inpatient stay and at 3 months of follow-up. Additional analysis was conducted comparing β-blocker therapy to any other antihypertensive treatment to determine a class-specific association of β-blocker treatment with mortality.

RESULTS:

The study population included 426 patients with acute, spontaneous ICH. Inpatient β-blocker use was independently associated with decreased rates of inpatient death and mortality at 3 months of follow-up. However, univariate and multivariable analyses comparing β-blocker use to other antihypertensives failed to show any class-specific reduction in mortality at either time point.

DISCUSSION:

Our study demonstrates that the improvement seen in patients treated with β-adrenergic antagonists is not an effect unique to this class. This supports ongoing trials to determine optimum levels of blood pressure control using multiple classes of antihypertensives.

© 2013.

KEYWORDS:

Antihypertensives; Beta-adrenergic antagonist; Blood pressure; Intracerebral hemorrhage; Stroke; Sympathetic nervous system

PMID:
24183854
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk